Formation of a Perbenzoic Acid Derivative in the Photodegradation of Fenofibrate: Phototoxicity Studies on Erythrocytes

Vargas, Franklin; Rivas, Carlos; Canudas, Nieves

doi:10.1002/jps.2600820609

Cited by 5 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fenofibrate is thought to be phototoxic secondary to free radical and singlet oxygen mechanisms consequent to the benzophenone chromophore structure of its numerous photoproducts. [150][151][152][153] The cross-reactivity in phototoxicity between ketoprofen-and fenofibrate-photosensitive subjects has been reported at 71% on patch testing. 145 Fenofibrate phototoxicity appears to be drug concentration-and ultraviolet A and ultraviolet B irradiation dose-dependent.…”

Section: Safety Adverse Eventsmentioning

confidence: 99%

Micronized Fenofibrate: A New Fibric Acid Hypolipidemic Agent

Guay

1999

Ann Pharmacother

View full text Add to dashboard Cite

Fenofibrate reduces serum TG, total cholesterol, and LDL-C, and raises HDL-C to clinically relevant degrees. Its spectrum of activity appears to exceed that recommended for types IV and V hyperlipidemia to encompass types IIa, IIb, and III hyperlipidemias as well. To this extent, it may be considered a broader-spectrum fibrate than is indicated by its FDA approval. Adverse effects of fenofibrate appear to be similar to those of other fibrates and require routine monitoring (clinical, liver function). Long-term safety data are readily available from drug registries in many countries where the product has been available for nearly two decades. Cost-effectiveness studies comparing fenofibrate with other hypolipidemics demonstrate benefits of fenofibrate over simvastatin in types IIa and IIb hyperlipidemia. The need for dosage titration of the micronized preparation from 67 mg/d upward to a final dose of 200 mg/d is also not supported by peer-reviewed literature (except in the case of renal impairment). Although preliminary data on plaque regression are encouraging, published clinical studies evaluating the impact of fenofibrate on cardiovascular morbidity and mortality are awaited. Micronized fenofibrate is worthy of formulary inclusion.

show abstract